市場調查報告書
商品編碼
1368670
胎牛血清市場規模 - 按產品類型(木炭剝離、色譜、外泌體去除)、應用(藥物發現、基於細胞的研究)、最終用戶和全球預測,2023-2032 年Fetal Bovine Serum Market Size - By Product Type (Charcoal Stripped, Chromatographic, Exosome Depleted), Application (Drug Discovery, Cell-based Research), End-user&, Global Forecast, 2023-2032 |
在多樣化細胞培養應用需求不斷成長的推動下,胎牛血清市場規模從 2023 年到 2032 年的年複合成長率預計將達到 8.1%。胎牛血清 (FBS) 在生物技術、製藥和研究等各個領域都變得非常重要,因為它為最佳細胞生長提供必需的營養素、生長因子和荷爾蒙。隨著細胞療法和再生醫學的激增,對高品質胎牛血清的需求也隨之加劇。
此外,對細胞培養應用研發活動的大量投資可能會支持整體市場的成長。例如,2023 年 7 月,默克集團在美國和加拿大的生命科學公司 MilliporeSigma 擴大了位於堪薩斯州萊內克薩的實驗室設施和製造能力,以生產細胞培養基。此外,一些市場參與者正在專注於開發新的創新產品,以滿足不斷成長的最終用戶需求。
胎牛血清市場按產品類型、應用、最終用戶和地區細分。
就產品類型而言,色譜領域的產業價值預計將在 2023 年至 2032 年間獲得顯著成長。這歸因於色譜在分離和純化胎牛血清成分中的應用不斷增加,以確保卓越的產品品質。此外,擴大採用先進的色譜技術,如高效液相層析 (HPLC) 和氣相層析 (GC),提高了胎牛血清純化的效率和精度,進一步促進了市場成長。
在應用方面,基於細胞的研究應用領域的胎牛血清市場預計到2032 年將錄得可觀收入。這一成長可歸因於FBS 在細胞培養和各種細胞研究活動(包括細胞生物學)中的日益採用、再生醫學和藥物開發。對先進細胞療法的日益關注以及對生命科學新應用的不斷探索也將影響該細分市場的成長。
歐洲胎牛血清市場預計將在 2023 年至 2032 年呈現健康成長。生物製藥和生物技術產業的強勁以及對研發活動的大量投資正在推動該地區對胎牛血清的需求。強調產品品質和安全的嚴格監管標準也刺激了優質胎牛血清的採用。此外,慢性病的盛行率不斷上升,加上對個人化醫療的日益重視,將增強產業前景。
Fetal Bovine Serum Market size is poised to witness 8.1% CAGR from 2023 to 2032, propelled by increasing demand in diverse cell culture applications. Fetal bovine serum (FBS) has grown profoundly important in various fields, including biotechnology, pharmaceuticals, and research as it provides essential nutrients, growth factors, and hormones for optimal cell growth . With the surge in cell-based therapies and regenerative medicine, the need for high-quality FBS has also intensified.
Additionally, massive investments in the R&D activities of cell culture applications are likely to support the overall market growth. For instance, in July 2023, MilliporeSigma, Merck KGaA's Life Science company in the U.S. and Canada expanded its lab facility and manufacturing capacity to produce cell culture media, in Lenexa, Kansas. Additionally, several market players are focusing on developing new and innovative products for catering to the rising end-user demand.
The fetal bovine serum market is segmented into product type, application, end-user, and region.
With respect to product type, the industry value from the chromatographic segment is projected to gain significant traction between 2023 and 2032. This is attributed to the increasing application of chromatography in isolating and purifying FBS components for ensuring superior product quality. Moreover, the increased adoption of advanced chromatographic techniques, such as high-performance liquid chromatography (HPLC) and gas chromatography (GC), is amplifying the efficiency and precision of FBS purification, further fostering the market growth.
In terms of application, the fetal bovine serum market from the cell-based research application segment is expected to record substantial revenue through 2032. The growth can be attributed to the increasing adoption of FBS in cell culture and various cellular research activities, including cell biology, regenerative medicine, and drug development. The escalating focus on advanced cell-based therapies and the continuous exploration of novel applications in life sciences will also influence the segment growth.
Europe fetal bovine serum market is expected to exhibit healthy growth from 2023 to 2032. The presence of robust biopharmaceutical and biotechnology sector along with substantial investments in R&D activities is fueling the demand for FBS in the region. Stringent regulatory standards for emphasizing product quality and safety are also stimulating the adoption of premium-grade FBS. Moreover, the increasing prevalence of chronic diseases coupled with the growing emphasis on personalized medicine will augment the industry outlook.